PharmaVOICE

PharmaVOICE.com is an online platform tailored for executives in the life sciences sector and professionals in healthcare services. It is created by PharmaLinx LLC, the same company that publishes PharmaVOICE magazine.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#630784

United States

#264301

Health/Biotechnology and Pharmaceuticals

#241

Traffic sources

Monthly visitors

Articles

HHS layoffs may be illegal, legal experts say

1 week ago | pharmavoice.com | Rebecca Pifer

This audio is auto-generated. Please let us know if you have feedback. The sweeping HHS layoffs have been chaotic and stressful for employees of the massive health department. They may also be illegal, according to lawyers and federal employment experts.
Novartis scores NFL deal to tackle health outcomes

1 week ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. When Novartis announced it was teaming up with the NFL last month, the company called it the first-ever corporate pharmaceutical partnership with the league. But it wasn’t exactly the only matchup between the industry and the professional football world. The NFL has inked several deals with pharma companies, starting with a 2003 sponsorship agreement that co-promoted a Bayer and GSK drug that was under FDA review.
Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

1 week ago | pharmavoice.com | Alexandra Wilson Pecci

This audio is auto-generated. Please let us know if you have feedback. Talk of pharma industry onshoring is reaching a fever pitch, with tariffs on foreign pharmaceuticals coming “very shortly,” Big Pharma companies pumping billions into U.S. manufacturing, and Eli Lilly and Merck & Co. partnering with Purdue University to launch an R&D manufacturing consortium to help boost U.S. production.
‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?

1 week ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. Stock market whiplash is dampening hopes for a comeback year in the biotech arena. Roughly 25% of biotech stock values sank below their cash holdings last week amid sudden changes to U.S. trade policy, Bloomberg reported. In an economic situation that’s shifting by the day, “the only thing that's certain is uncertainty,” said David Crean, managing partner at M&A consulting firm Cardiff Advisory.
The fallout from UnitedHealth’s CEO slaying

1 week ago | pharmavoice.com | Meagan Parrish

This audio is auto-generated. Please let us know if you have feedback. What started as the shocking murder of a healthcare executive has now become a watershed moment for an entire industry. Brian Thompson, the CEO of UnitedHealthcare, was gunned down in December while walking along a Manhattan sidewalk. After an intense manhunt, the suspected assailant was caught and identified as Luigi Mangione. The case against 26-year-old Mangione, which includes state and federal charges, is moving swiftly.
Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model

1 week ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. As the pharmaceutical industry wrestles with the prospect of U.S. tariffs and global retaliation that could cut into future profits, the changing dynamic has industry leaders considering capital allocation strategies that could shift priorities in a meaningful way.
Pharma’s manufacturing moment: Where companies are making the biggest moves

1 week ago | pharmavoice.com | Meagan Parrish

This audio is auto-generated. Please let us know if you have feedback. The U.S.’s billowing trade policies rattled global markets this week with the onset of new tariffs that were then mostly paused. Although the uncertainty took a bite out of Big Pharma stocks, the industry was mostly spared from the worst of the upheaval.
Trump’s tariff tirade and sudden calm keep Big Pharma on its toes

2 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. Following a week of President Donald Trump’s tariff tornado ripping through Wall Street, wiping out trillions in market value, the administration’s about-face on trade yesterday sent stocks soaring. Still, pharma companies that were spared from the taxes on imported goods have been spinning in the high winds.
US risks losing biotech edge to China, report warns

2 weeks ago | pharmavoice.com | Ned Pagliarulo

This audio is auto-generated. Please let us know if you have feedback. The U.S. risks losing a once-decisive edge over China in biotechnology unless the federal government prioritizes the sector’s advancement with new funding and policies, a bipartisan commission warned in a report issued Tuesday. At minimum, the commission wrote, the U.S. should invest at least $15 billion over the next five years to strengthen the country’s biotech capabilities.
Big Pharma is rewriting the R&D playbook to account for seismic shifts in the investment landscape

2 weeks ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. With $16.9 billion in sales in 2024 alone, Novo Nordisk has clearly received huge R&D returns from its blockbuster obesity and diabetes drugs Ozempic and Wegovy. And it’s not alone among companies cashing in. R&D returns for 2024 rose to 5.9% for the top 20 biopharma companies, up from about 4% the year before and continuing a year-over-year upward climb, according to forecasts in a new Deloitte report.